Navigation Links
Royal Fornia Electronic Device Co., Ltd. Signs Technology Licensing Agreement to Integrate Masimo rainbow SET Pulse CO-Oximetry Into New Patient Monitors
Date:2/24/2011

m/prnews?Page=Quote&Ticker=MASI"> MASI) is the global leader in innovative noninvasive monitoring technologies that significantly improve patient care—helping solve "unsolvable" problems.  In 1995, the company debuted Measure-Through Motion and Low Perfusion pulse oximetry, known as Masimo SET®, which virtually eliminated false alarms and increased pulse oximetry's ability to detect life-threatening events.  More than 100 independent and objective studies demonstrate Masimo SET provides the most reliable SpO2 and pulse rate measurements even under the most challenging clinical conditions, including patient motion and low peripheral perfusion.  In 2005, Masimo introduced rainbow® SET Pulse CO-Oximetry™ technology, allowing noninvasive and continuous monitoring of blood constituents that previously required invasive procedures, including total hemoglobin (SpHb®), oxygen content (SpOC™), carboxyhemoglobin (SpCO®), methemoglobin (SpMet®), and Pleth Variability Index (PVI®), in addition to SpO2, pulse rate, and perfusion index (PI).  In 2008, Masimo introduced Patient SafetyNet™, a remote monitoring and wireless clinician notification system designed to help hospitals avoid preventable deaths and injuries associated with failure to rescue events.  In 2009, Masimo introduced rainbow Acoustic Monitoring™, the first-ever noninvasive and continuous monitoring of acoustic respiration rate (RRa™).  Masimo's rainbow SET technology platform offers a breakthrough in patient safety by helping clinicians detect life-threatening conditions and helping guide treatment options.  In 2010, Masimo acquired SEDLine®, a pioneer in the development of innovative brain function monitoring technology and devices.  Masimo SET and Masimo rainbow SET technologies can be also found in over 100 multiparameter patient monitors from over 50 medical device manufacturers around the world.
'/>"/>
SOURCE Masimo Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Paul Capital Healthcare Purchases Additional Royalty Interest in GlaxoSmithKlines Rotarix(R)
2. Alseres Pharmaceuticals Enters Agreement to Amend Cethrin(R) License to Lower Milestone Payments and Royalty Rates
3. Beckman Coulter Buys Out Royalty Obligation for Preeclampsia Markers
4. Neurobiological Technologies Reports Receipt of $1.5 Million Royalty Payment for Quarterly Sales of Memantine
5. Royalty Pharma Announces that Alexander von Perfall Joins Management Team
6. Royal Institute of Technology Adopts OriGene Over-Expression Lysates in Human Proteome Atlas Program
7. Unilens Vision Reports Record First Quarter Earnings and Royalty Income
8. Almac and the Royal Society of Chemistry Host a Workshop on the use of Analytical Techniques to Control and Monitor Solid Form
9. Ramius and Royalty Pharma Extend Tender Offer Until January 5, 2011 Pursuant to Definitive Merger Agreement
10. Ramius and Royalty Pharma Announce Successful Conclusion of Cypress Bioscience Tender Offer
11. Titan Reports Fourth Quarter 2010 Fanapt® Royalty
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... N.J., Feb. 27, 2015  PTC Therapeutics, Inc. (NASDAQ: ... and reported financial results for the fourth quarter and ... "2014 was a transformative year for PTC. We are ... and developing RNA-targeted therapies in the rare disease space," ... Therapeutics, Inc. "We are proud to bring the first ...
(Date:2/27/2015)...  Bionik Laboratories Corp. (OTC:DWTPD), a Delaware ... acquired Bionik Laboratories, Inc., a Toronto ... qualified accredited investors of units consisting of its common ... $6.2 million. Shares of the Company,s common stock will ... the symbol "DWTPD" until FINRA,s approval of the ticker ...
(Date:2/26/2015)... , February 27, 2015 ... H2 2014 market research report to its store. ... Corneal Ulcers, therapeutic pipeline. The report ... on the therapeutic development for Corneal Ulcers. Corneal ... that includes bacterial infections, viral infections & fungal ...
Breaking Medicine Technology:PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 2PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 3PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 4PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 5PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 6PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 7PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 8PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 9PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 10PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 11Bionik Laboratories Raises $6.2 Million 2Bionik Laboratories Raises $6.2 Million 3Corneal Ulcers Therapeutics Companies and Drugs Pipeline H2 2014 Review Research Report 2Corneal Ulcers Therapeutics Companies and Drugs Pipeline H2 2014 Review Research Report 3Corneal Ulcers Therapeutics Companies and Drugs Pipeline H2 2014 Review Research Report 4Corneal Ulcers Therapeutics Companies and Drugs Pipeline H2 2014 Review Research Report 5
... , April 29 Abraxis BioScience initially ... the former ICN/Valient Pharmaceutical building in Costa Mesa, ... foot building. The "due diligence report" revealed an array ... occupying the building, and once the building purchase was ...
... April 29 Dendreon Corporation (Nasdaq: ... Food and Drug Administration (FDA) has approved PROVENGE® ... of asymptomatic or minimally symptomatic metastatic, castrate-resistant (hormone-refractory) ... an immune response against prostatic acid phosphatase (PAP), ...
Cached Medicine Technology:LCS Constructors, Inc. Completes First Major Phase of Abraxis BioScience Project 2FDA Approves PROVENGE(R) for the Treatment of Men with Advanced Prostate Cancer 2FDA Approves PROVENGE(R) for the Treatment of Men with Advanced Prostate Cancer 3FDA Approves PROVENGE(R) for the Treatment of Men with Advanced Prostate Cancer 4FDA Approves PROVENGE(R) for the Treatment of Men with Advanced Prostate Cancer 5FDA Approves PROVENGE(R) for the Treatment of Men with Advanced Prostate Cancer 6FDA Approves PROVENGE(R) for the Treatment of Men with Advanced Prostate Cancer 7
(Date:3/1/2015)... Michigan (PRWEB) March 01, 2015 Women’s ... to treat Overactive Bladder (OAB) symptoms, such as a strong ... when another type of medication (anticholinergic) does not work well ... treatment option that takes another approach to targeting the source ... works on the nerves and bladder muscle, blocking the signals ...
(Date:3/1/2015)... (PRWEB) March 01, 2015 Researchers say ... that so many sheet metal workers contract malignant mesothelioma. ... new report on its website. Click here to ... for Construction Research and Training monitored 17,345 sheet metal ... disproportionate number of them died of mesothelioma or ...
(Date:3/1/2015)... The number of transvaginal mesh lawsuits ( ... weeks in two New Jersey litigations where attorneys at ... announces. , A Case List updated on February ... proceeding established for products manufactured by Johnson & Johnson's ... when 90 fewer cases had been centralized. Additionally, 1,700 ...
(Date:3/1/2015)... “ The Barrel Mill ” was featured on NewsWatch as ... at the latest and coolest technology products and services available ... technology expert, conducted the review and shared with viewers how ... to Home Distillation of Alcohol, it's understood that oak is ... cool product that’ll help anyone achieve a barrel aged alcohol ...
(Date:2/28/2015)... (PRWEB) February 28, 2015 The MCA ... across Malaysia into one platform and gears towards the ... , A series of group talks in smaller groups ... Nation Building, Education, Personal Development, Leadership, Entrepreneurship, Healthcare, Social ... raise awareness of Malaysian youths. , Young ...
Breaking Medicine News(10 mins):Health News:Women's Excellence Now Offers BOTOX For Overactive Bladder Treatment 2Health News:New Study Finds Indirect Asbestos Exposure Can Raise Mesothelioma Risk for Sheet Metal Workers, According to Surviving Mesothelioma 2Health News:Bernstein Liebhard LLP Comments on Case List Growth in New Jersey Transvaginal Mesh Litigations, Where Firm Attorneys are Representing Hundreds 2Health News:Bernstein Liebhard LLP Comments on Case List Growth in New Jersey Transvaginal Mesh Litigations, Where Firm Attorneys are Representing Hundreds 3Health News:Bernstein Liebhard LLP Comments on Case List Growth in New Jersey Transvaginal Mesh Litigations, Where Firm Attorneys are Representing Hundreds 4Health News:An Oak Infusion Spiral was Featured on NewsWatch Television on January 30, 2015 2Health News:My Mobile University Appointed Learning Partner for the Upcoming MCA’S First Youth Empowerment Conference Held in Malaysia on March 28, 2015 2Health News:My Mobile University Appointed Learning Partner for the Upcoming MCA’S First Youth Empowerment Conference Held in Malaysia on March 28, 2015 3Health News:My Mobile University Appointed Learning Partner for the Upcoming MCA’S First Youth Empowerment Conference Held in Malaysia on March 28, 2015 4
... (Nasdaq: ANSV ) today announced that that John ... the following events in,November: Rodman & Renshaw 9th ... p.m. ET Presentation: http://www.wsw.com/webcast/rrshq12/ansv , 19th ... 4:30 p.m. ET Presentation: http://www.piperjaffray.com/conferences , ...
... Near-term Pipeline of Products Designed to Deter ... Common Methods of ... ,King Pharmaceuticals, Inc. (NYSE: KG ) and Acura Pharmaceuticals, ... entered into,a License, Development and Commercialization Agreement (the "Agreement"),for the ...
... New business awards a record $175 million; net book-to-bill of 1.7:1, - Total business ... margin of 14.2% (GAAP) and 15.3% (proforma) ... revenues of $100.1 million, up 33% over third quarter ... ...
... StemCor Systems, Inc., a,medical device company developing ... it has received 510(k) clearance from,the U.S. ... its MarrowMiner(TM),for the harvest of bone marrow. ... clearance of StemCor,s MarrowMiner is a major,accomplishment ...
... Oct. 30 Barack Obama today,stepped ahead of all ... areas of foreign policy, the effort to eradicate extreme ... area, he pledged to,increase spending on global HIV/AIDS to ... time increasing overall foreign assistance spending to,$50 billion annually. ...
... $45 Million Reflecting 79% Growth Over Prior Year Quarter; ... Guidance and Reaffirms 2008 Guidance, COEUR D,ALENE, Idaho, ... ), the leading provider of radiology,solutions to radiology groups ... third quarter ended September 30, 2007. Revenue,grew 79% year-over-year ...
Cached Medicine News:Health News:Anesiva Announces Upcoming Webcasts and Conference Participation 2Health News:King Pharmaceuticals and Acura Pharmaceuticals Enter Agreement to Develop and Commercialize Immediate Release Pain Medicines Utilizing Acura's Aversion(R) (Abuse-Deterrent) Technology 2Health News:King Pharmaceuticals and Acura Pharmaceuticals Enter Agreement to Develop and Commercialize Immediate Release Pain Medicines Utilizing Acura's Aversion(R) (Abuse-Deterrent) Technology 3Health News:King Pharmaceuticals and Acura Pharmaceuticals Enter Agreement to Develop and Commercialize Immediate Release Pain Medicines Utilizing Acura's Aversion(R) (Abuse-Deterrent) Technology 4Health News:King Pharmaceuticals and Acura Pharmaceuticals Enter Agreement to Develop and Commercialize Immediate Release Pain Medicines Utilizing Acura's Aversion(R) (Abuse-Deterrent) Technology 5Health News:King Pharmaceuticals and Acura Pharmaceuticals Enter Agreement to Develop and Commercialize Immediate Release Pain Medicines Utilizing Acura's Aversion(R) (Abuse-Deterrent) Technology 6Health News:Kendle Delivers Record Sales and Backlog and Strong Growth in Operating Margin for Third Quarter 2007 2Health News:Kendle Delivers Record Sales and Backlog and Strong Growth in Operating Margin for Third Quarter 2007 3Health News:Kendle Delivers Record Sales and Backlog and Strong Growth in Operating Margin for Third Quarter 2007 4Health News:Kendle Delivers Record Sales and Backlog and Strong Growth in Operating Margin for Third Quarter 2007 5Health News:Kendle Delivers Record Sales and Backlog and Strong Growth in Operating Margin for Third Quarter 2007 6Health News:Kendle Delivers Record Sales and Backlog and Strong Growth in Operating Margin for Third Quarter 2007 7Health News:Kendle Delivers Record Sales and Backlog and Strong Growth in Operating Margin for Third Quarter 2007 8Health News:Kendle Delivers Record Sales and Backlog and Strong Growth in Operating Margin for Third Quarter 2007 9Health News:StemCor Systems Receives FDA Clearance for Bone Marrow Harvesting System 2Health News:StemCor Systems Receives FDA Clearance for Bone Marrow Harvesting System 3Health News:Obama Pledges Major Expansion of AIDS and Global Poverty Programs 2Health News:NightHawk Radiology Holdings, Inc. Releases Record Third Quarter 2007 Results 2Health News:NightHawk Radiology Holdings, Inc. Releases Record Third Quarter 2007 Results 3Health News:NightHawk Radiology Holdings, Inc. Releases Record Third Quarter 2007 Results 4Health News:NightHawk Radiology Holdings, Inc. Releases Record Third Quarter 2007 Results 5Health News:NightHawk Radiology Holdings, Inc. Releases Record Third Quarter 2007 Results 6Health News:NightHawk Radiology Holdings, Inc. Releases Record Third Quarter 2007 Results 7Health News:NightHawk Radiology Holdings, Inc. Releases Record Third Quarter 2007 Results 8Health News:NightHawk Radiology Holdings, Inc. Releases Record Third Quarter 2007 Results 9Health News:NightHawk Radiology Holdings, Inc. Releases Record Third Quarter 2007 Results 10Health News:NightHawk Radiology Holdings, Inc. Releases Record Third Quarter 2007 Results 11Health News:NightHawk Radiology Holdings, Inc. Releases Record Third Quarter 2007 Results 12Health News:NightHawk Radiology Holdings, Inc. Releases Record Third Quarter 2007 Results 13Health News:NightHawk Radiology Holdings, Inc. Releases Record Third Quarter 2007 Results 14Health News:NightHawk Radiology Holdings, Inc. Releases Record Third Quarter 2007 Results 15Health News:NightHawk Radiology Holdings, Inc. Releases Record Third Quarter 2007 Results 16
Performa cemented stem....
Porous foundation 480 series....
Porous foundation 440 series....
A cementless femoral stem that promotes bone in-growth and reduces thigh pain....
Medicine Products: